Clinical trial approval / initiation

Explore the landscape of Clinical trial approval / initiation in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial approval / initiation to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

CompanyDeals

GeneScience Acquires Global Rights to Megestrol Acetate Oral Suspension from TWi Pharmaceuticals – $100M Deal Transforms Distributor into MAH for Cachexia Therapy

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its controlled subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. — through its wholly‑owned subsidiary GENSCI Singapore Pte. Ltd. —…

ApicHope's Oral Small‑Molecule GLP‑1R Agonist APH04935 Wins FDA IND Approval – Once‑Daily Pill Targets Obesity in Competitive Weight Loss Market

ApicHope’s Oral Small‑Molecule GLP‑1R Agonist APH04935 Wins FDA IND Approval – Once‑Daily Pill Targets Obesity in Competitive Weight Loss Market

Biocause Heilen Wins NMPA Approval for Ibuprofen Arginine Granules – Enhanced‑Solubility NSAID Enters China's OTC Analgesic Market

Biocause Heilen Wins NMPA Approval for Ibuprofen Arginine Granules – Enhanced‑Solubility NSAID Enters China’s OTC Analgesic Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Kanghong Pharmaceutical's NASH Drug KH629 Receives Clinical Trial Implicit Approval in China
CompanyDrug

Kanghong Pharmaceutical’s NASH Drug KH629 Receives Clinical Trial Implicit Approval in China

Akeso Biopharma Launches Phase Ib/II Trial for Cadonilimab and AK112 in Pancreatic Cancer
CompanyDrug

Akeso Biopharma Launches Phase Ib/II Trial for Cadonilimab and AK112 in Pancreatic Cancer

Shenzhen Chipscreen Advances CS231295 for Cancer Treatment as IND Accepted by NMPA
CompanyDrug

Shenzhen Chipscreen Advances CS231295 for Cancer Treatment as IND Accepted by NMPA

Laekna Advances Obesity Treatment Candidate LAE102 with Subcutaneous Dosing in Phase I Study
CompanyDrug

Laekna Advances Obesity Treatment Candidate LAE102 with Subcutaneous Dosing in Phase I Study

Alphamab Oncology and CSPC Pharma's KN026 Phase III Trial for Breast Cancer Gets NMPA Approval
CompanyDrug

Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval

Innovec Pharma's IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China's CDE
CompanyDrug

Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer
CompanyDrug

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer

Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study
CompanyDrug

Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study

Show More